Portfolio
The following chart provides an overview of our product candidates currently in development as of the date of the publication of this report.
*Subject to opt-in under collaboration and exclusive license agreement with Adaptimmune for uza-cel (ADP-A2M4CD8) (signed & announced 30 May 2024); **uza-cel produced on Galapagos’ decentralized manufacturing platform
Product candidate
Substance that has satisfied the requirements of early preclinical testing and has been selected for development, starting with formal preclinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans